Opinion 2 Feb 2023 How digital biomarker assays can harness the power of deep learning from clinical trials to the clinic By Joe Oakley, MD, medical director of biomarker development, Paige Just as much of medicine has begun to undergo a digital transformation in the past decade, so has pathology. Now, biomarkers, which are indications of particular features of cancer and are essential to diagnosis and treatment, are beginning their own digital revolution. This is an […] February 2, 2023 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 1 Feb 2023 Foundation for the National Institutes of Health: partnering to tackle cancer The Foundation for the National Institutes of Health (FNIH) takes on cancer through public-private research partnerships on prevention and early diagnosis. Dr Stacey Adam is associate vice president for research partnerships at the Foundation for the National Institutes of Health. In her role, she leads the cancer research partnership programs. Adam is a molecular pharmacologist/cancer […] February 1, 2023 - 8 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2023 Cancer Genomics: Technological innovation set to fuel research breakthroughs By Neil Ward, vice President and general manager, PacBio EMEA We’ve known for a long time that genomic sequencing can strengthen our understanding of cancer’s highly complex and variable pathology. But to date, embedding genomics into cancer research has been challenging because of limitations in sequencing technology. But with recent innovations, this is changing. Genomic […] February 1, 2023 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jan 2023 Ibex to collaborate with AstraZeneca and Daiichi Sankyo on AI breast cancer product Ibex Medical Analytics has announced an agreement with AstraZeneca and Daiichi Sankyo, for the development, clinical validation and early adoption of an AI-powered product to aid pathologists with an accurate and reproducible assessment of HER2 immunohistochemistry (IHC) scoring in breast cancer patients. Scoring of HER2 (human epidermal growth factor receptor 2) protein expression in breast […] January 26, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jan 2023 CytoReason expands deal with Sanofi to look at IBD CytoReason, which creates computational disease modeling, has announced an expansion of its collaboration with Sanofi. The multi-year collaboration will further fuel Sanofi’s target discovery efforts via CytoReason’s AI platform in the field of inflammatory bowel disease (IBD), to identify patient subtypes and pair them with IBD targets. In 2021, Cytoreason announced the initiation of a […] January 24, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 19 Jan 2023 Interview: Proscia talks about digital pathology Labiotech recently interviewed Nathan Buchbinder, chief product officer at Proscia, about digital pathology. AI has been a hot topic in drug discovery. Can you outline how it’s being applied to pathology data? Sure, it’s always great to start with such an exciting topic! There are two broad applications of AI that I want to highlight. […] January 19, 2023 - 8 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2023Beyond Biotech podcast 29: Janssen, Knowledge Gate This week, our guests are Viktoriya Vasilenko, Knowledge Gate co-founder and CEO; and Avery Ince, vice president, medical affairs, cardiovascular & metabolism at Janssen Scientific Affairs, LLC. Study confirms benefit of XARELTO (rivaroxaban) for secondary prevention of venous thromboembolism in cancer patients The Janssen Pharmaceutical Companies of Johnson & Johnson has revealed observational data from […] January 12, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 What’s in store for biotech in 2023? Perhaps 2022 will best be remembered in the life science industry for the return of many of the face-to-face events that fell by the wayside during the COVID-19 pandemic. It might have been a mixed year for biotech companies, but 2023 is a new year, with new challenges, but also new opportunities. So what do […] January 11, 2023 - 14 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Poolbeg identifies new potential drug candidates for RSV infections Poolbeg Pharma says it has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) program with OneThree Biotech, Inc. Since initiating the collaboration in February 2022, Poolbeg’s scientific team has worked with OneThree to build a tailored AI approach that leverages Poolbeg’s RSV human challenge trial data to identify […] December 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Dec 2022 Cyclica and SK Chemicals to co-develop novel therapeutics Cyclica Inc. and SK Chemicals Co., Ltd. have announced an AI-driven drug discovery and development partnership to develop therapies across a range of disease areas. Under this collaboration, Cyclica will deploy its proprietary drug discovery platforms to identify novel drug candidates for challenging biological targets across therapeutic areas of mutual interest to both companies. SK […] December 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2022 Etcembly reveals breakthrough in optimizing TCR assets Etcembly has announced the successful prediction and optimization of multiple T cell receptor (TCR) assets for targeting leukemias and solid tumors. The company’s machine learning platform EMLy (Etcembly machine learning) enables AI based engineering of novel TCRs from the complete theoretical TCR repertoire. The unification of machine-learning-based optimization with empirical validation has facilitated the rapid […] December 14, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2022 PhoreMost and ThinkCyte collaborate on AI-based drug discovery PhoreMost Ltd. and ThinkCyte K.K have announced a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI). The partnership leverages both companies’ technologies in high-throughput drug discovery. These are PhoreMost’s next-generation phenotypic screening platform, SITESEEKER, and ThinkCyte’s AI-driven cell characterization and sorting platform, Ghost Cytometry. The aim is to develop […] December 14, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email